Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPTLC1 | O15269 | 1/20 | 0.76 |
| ▸ | SPTLC2 | O15270 | 1/20 | 0.76 |
| ▸ | FAAH | O00519 | 2/20 | 0.49 |
| ▸ | CNR1 | P21554 | 1/20 | 0.46 |
| ▸ | MME | P08473 | 6/20 | 0.44 |
| ▸ | ACE | P12821 | 6/20 | 0.44 |
| ▸ | CPA1 | P15085 | 2/20 | 0.44 |
| ▸ | ACE2 | Q9BYF1 | 2/20 | 0.44 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.40 |
| ▸ | PSMB11 | A5LHX3 | 1/20 | 0.39 |
| ▸ | PSMA7 | O14818 | 1/20 | 0.39 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.39 |
| ▸ | PSMA1 | P25786 | 1/20 | 0.39 |
| ▸ | PSMA2 | P25787 | 1/20 | 0.39 |
| ▸ | PSMA3 | P25788 | 1/20 | 0.39 |
| ▸ | PSMA4 | P25789 | 1/20 | 0.39 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16944314 | 0.94 | SPTLC1 (0.68) | SPTLC1SPTLC2FAAHCNR1MME | |
| SCHEMBL17518727 | 0.94 | SPTLC1 (0.68) | SPTLC1SPTLC2FAAHCNR1GRIA1 | |
| SCHEMBL16944362 | 0.93 | SPTLC1 (0.67) | SPTLC1SPTLC2FAAHCNR1GRIA1 | |
| SCHEMBL16944292 | 0.93 | SPTLC1 (0.69) | SPTLC1SPTLC2FAAHCNR1MME | |
| SCHEMBL16944319 | 0.93 | SPTLC1 (0.67) | SPTLC1SPTLC2FAAHCNR1MME | |
| SCHEMBL10082711 | 0.93 | SPTLC1 (0.76) | SPTLC1SPTLC2FAAHCNR1MME | |
| SCHEMBL6802874 | 0.93 | SPTLC1 (0.76) | SPTLC1SPTLC2FAAHCNR1MME | |
| SCHEMBL31618543 | 0.93 | SPTLC1 (0.75) | SPTLC1SPTLC2FAAHMMEACE | |
| SCHEMBL6804868 | 0.92 | SPTLC1 (0.75) | SPTLC1SPTLC2FAAHMMEACE | |
| SCHEMBL14190672 | 0.92 | SPTLC1 (0.75) | SPTLC1SPTLC2FAAHMMEACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220288004-A1 | TREATMENT AND PREVENTION OF AGING RELATED-DISEASE AND/OR AGING BY THE INHIBITION OF SPHINGOLIPIDS | ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (EPFL) (CH) | 2022-09-15 | — | — | US | disclosed |
| US-20150210666-A1 | ORALLY AVAILABLE VIRIDIOFUNGIN DERIVATIVE POSSESSING ANTI-HCV ACTIVITY | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2015-07-30 | — | — | US | disclosed |
| US-20150148387-A1 | METHODS OF TREATMENT, DIAGNOSIS AND MONITORING FOR METHAMPHETAMINE TOXICITY WHICH TARGET CERAMIDE METABOLIC PATHWAYS AND CELLULAR SENESCENCE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2015-05-28 | — | — | US | disclosed |
| US-20150148387-A1 | METHODS OF TREATMENT, DIAGNOSIS AND MONITORING FOR METHAMPHETAMINE TOXICITY WHICH TARGET CERAMIDE METABOLIC PATHWAYS AND CELLULAR SENESCENCE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2015-05-28 | — | — | US | disclosed |
| WO-2013149250-A1 | METHODS OF TREATMENT, DIAGNOSIS AND MONITORING FOR METHAMPHETAMINE TOXICITY WHICH TARGET CERAMIDE METABOLIC PATHWAYS AND CELLULAR SENESCENCE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-10-03 | — | — | WO | disclosed |
| US-8183005-B1 | Pharmaceutical agents for treating HCV infections | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2012-05-22 | — | — | US | disclosed |
| US-8183005-B1 | Pharmaceutical agents for treating HCV infections | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2012-05-22 | — | — | US | disclosed |
| US-20110160252-A1 | PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OR PREVENTION OF HBV INFECTION | PUBLIC UNIVERSITY CORPORATION NAGOYA CITY UNIVERSITY (JP) | 2011-06-30 | — | — | US | disclosed |
| US-20110160252-A1 | PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OR PREVENTION OF HBV INFECTION | PUBLIC UNIVERSITY CORPORATION NAGOYA CITY UNIVERSITY (JP) | 2011-06-30 | — | — | US | disclosed |
| US-20110098477-A1 | Method Of Producing Compound Having Anti-Hcv Activity | CHUGAI SEIYAKU KABUSHIKI KAISHA | 2011-04-28 | — | — | US | disclosed |
| US-7897783-B2 | Intermediate compound for synthesis of viridiofungin a derivative | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2011-03-01 | — | — | US | disclosed |
| US-20100274026-A1 | Virus therapeutic drug | CHUGAI SEIYAKU KABUSHIKI KAISHA | 2010-10-28 | — | — | US | disclosed |
| US-20100274026-A1 | Virus therapeutic drug | CHUGAI SEIYAKU KABUSHIKI KAISHA | 2010-10-28 | — | — | US | disclosed |
| US-7776918-B2 | Remedy for viral disease | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2010-08-17 | — | — | US | disclosed |
| US-7776918-B2 | Remedy for viral disease | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2010-08-17 | — | — | US | disclosed |
| US-20080293950-A1 | Production Process of Compound Having Anti-Hcv Action and Intermediate Thereof | CHUGAI SEIYAKU KABUSHIKI KAISHA | 2008-11-27 | — | — | US | disclosed |
| US-7378446-B2 | Compound having anti-HCV activity and process for producing the same | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2008-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150148387-A1 | METHODS OF TREATMENT, DIAGNOSIS AND MONITORING FOR METHAMPHETAMINE TOXICITY WHICH TARGET CERAMIDE METABOLIC PATHWAYS AND CELLULAR SENESCENCE | CERS2, CHKB, CES2 | SPTLC1 30/4885SPTLC2 15/4885FAAH 80/4885 |
| US-20220288004-A1 | TREATMENT AND PREVENTION OF AGING RELATED-DISEASE AND/OR AGING BY THE INHIBITION OF SPHINGOLIPIDS | SMPD3, SMPD2, SMPD1 | SPTLC1 7/4885SPTLC2 6/4885FAAH 124/4885 |
| US-20150210666-A1 | ORALLY AVAILABLE VIRIDIOFUNGIN DERIVATIVE POSSESSING ANTI-HCV ACTIVITY | ZC3HAV1, SLC10A1, CYP51A1 | SPTLC1 1254/4885SPTLC2 2323/4885FAAH 2913/4885 |
| US-20080293950-A1 | Production Process of Compound Having Anti-Hcv Action and Intermediate Thereof | HCCS, EIF2AK2, MAVS | SPTLC1 3812/4885SPTLC2 4077/4885FAAH 4333/4885 |
| US-20110098477-A1 | Method Of Producing Compound Having Anti-Hcv Activity | ERG28, HCCS, BCAT2 | SPTLC1 925/4885SPTLC2 2385/4885FAAH 3257/4885 |
| US-20100274026-A1 | Virus therapeutic drug | HAVCR2, ZC3HAV1, EIF2AK2 | SPTLC1 2899/4885SPTLC2 2848/4885FAAH 4349/4885 |
| US-20110160252-A1 | PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OR PREVENTION OF HBV INFECTION | IFNG, HDGF, HAVCR2 | SPTLC1 4049/4885SPTLC2 4400/4885FAAH 2496/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.